PROGNOSTIC IMPLICATIONS OF PLASMA-LEVELS OF ATRIAL-NATRIURETIC-FACTOR IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION

被引：6

作者：

NAKAMURA, M

ARAKAWA, N

YOSHIDA, H

FUNAKOSHI, T

CHIBA, M

MAKITA, S

AOKI, H

HIRAMORI, K

机构：

[1] Second Department of Internal Medicine, Iwate Medical University, Morioka

来源：

INTERNAL MEDICINE | 1993年 / 32卷 / 02期

关键词：

PROGNOSIS; HEART FAILURE; MORTALITY; HEMODYNAMICS; ATRIAL PRESSURE; AGE;

D O I：

10.2169/internalmedicine.32.112

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Several neurohormonal factors have been proposed as markers of the severity of acute myocardial infarction (MI). To determine whether plasma concentrations of atrial natriuretic factor (ANF) might predict post-MI prognosis, we studied 130 patients with acute MI (97 males and 33 females, mean age 62 years). Within one-half to one day after admission, a blood sample was taken for estimation of circulating ANF. The mean follow-up period was 37 months, and the follow-up rate was 97%. Of the 130 patients, 28 died from cardiac causes during the follow-up period. Patients were classified into three groups according to plasma ANF levels (group 1, < 99 pg/ml; group 2, 100-199 pg/ml; group 3 > 200 pg/ml). The survival curves were constructed by the Kaplan-Meier method. There were significant differences in the cumulative survival rate among the three groups (group 1 > group 2 > group 3; p < 0.001). The baseline characteristics (age, atrial pressure, and cardiac index) were different among the groups, therefore these variables were analyzed by a Cox multiple regression model. Significant predictors of cardiac mortality were plasma ANF class (p < 0.002) and pulmonary capillary wedge pressure (p < 0.007). In conclusion, these observations demonstrated that stratification of acute MI patients by plasma ANF level is a useful non-invasive method for predicting prognosis and for identifying individuals at high risk of cardiac death.

引用

页码：112 / 115

页数：4

共 18 条

[11]

Shell W.E., DeWood M.A., Peter T., Et al., Comparison of clinical signs and hemodynamic state in the early hours of transmural myocardial infarction, Am Heart J, 104, (1982)

[12]

Breuhaus B.A., Saneii H.H., Brandt M.A., Chimoskey J.E., Atriopeptin II lowers cardiac output in conscious sheep, Am J Physiol, 18, (1985)

[13]

Wangler R.D., Breuhaus B.A., Otero H.O., Et al., Coronary vasoconstrictor effects of atriopeptine, Science, 230, 2, (1985)

[14]

Awazu M., Imada T., Kon V., Et al., Role of endogenous atrial natriuretic peptide in congestive heart failure, Am J Physiol, 257, (1989)

[15]

Keller N., Sykulski R., Larsen J., Effects of dobutamine and salbutamol on haemodynamics and atrial natriuretic factor in patients with severe congestive heart failure, Clin Physiol, 11, (1991)

[16]

Webster M.W.I., Sharpe N., Coxon R., Et al., Effects of reducing atrial pressure on atrial natriuretic factor and vasoactive hormones in congestive heart failure secondary to ischemic and nonischemic dilated cardiomyopathy, Am J Cardiol, 63, (1989)

[17]

Haufe M.C., Gerzer R., Weil J., Ernst J.E., Theisen K., Verapamil impairs secretion of stimulated atrial natriuretic factor in humans, J Am Coll Cardiol, 11, (1988)

[18]

Svanegaard J., Angelo-Nielsen K., Pindborg T., Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarction, Br Heart J, 68, (1992)

← 1 2 →